Drug
AK002 clinical trials
Also written AK002 and Lirentelimab.
- studies test it
- 14
- open now
- 0
- in phase 3
- 5
- first study started
- 2016
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 4 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 6
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Allakos Inc. (14)
Studies
Open first, then newest update. How each study uses AK002 is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic DermatitisTerminatedPhase 2Allakos Inc.NCT05155085Written as AK002
- A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous UrticariaTerminatedPhase 2Allakos Inc.NCT05528861Written as Lirentelimab (AK002)
- An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)CompletedPhase 3Allakos Inc.NCT04620811Written as lirentelimab
- A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic UrticariaCompletedPhase 2Allakos Inc.NCT03436797Written as AK002
- An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic DuodenitisCompletedPhase 2Allakos Inc.NCT03664960Written as AK002
- A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic GastroenteritisCompletedPhase 2Allakos Inc.NCT03496571Written as AK002
- A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic DuodenitisCompletedPhase 3Allakos Inc.NCT04856891Written as AK002
- A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)CompletedPhase 3Allakos Inc.NCT04322604Written as lirentelimab (AK002)
- A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic EsophagitisCompletedPhase 2/3Allakos Inc.NCT04322708Written as lirentelimab (AK002)
- A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy VolunteersCompletedPhase 1Allakos Inc.NCT04324268Written as lirentelimab (AK002)
- A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic DuodenitisWithdrawnPhase 3Allakos Inc.NCT05152563Written as AK002
- A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic ConjunctivitisCompletedPhase 1Allakos Inc.NCT03379311Written as AK002
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002CompletedPhase 1Allakos Inc.NCT02808793Written as AK002
- Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy ParticipantsCompletedPhase 1Allakos Inc.NCT02859701Written as AK002